TY - JOUR
T1 - Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation
AU - Roy, Tithi
AU - Banang-Mbeumi, Sergette
AU - Boateng, Samuel T.
AU - Ruiz, Emmanuelle M.
AU - Chamcheu, Roxane Cherille N.
AU - Kang, Lin
AU - King, Judy A.
AU - Walker, Anthony L.
AU - Nagalo, Bolni Marius
AU - Kousoulas, Konstantin G.
AU - Esnault, Stephane
AU - Huang, Shile
AU - Chamcheu, Jean Christopher
N1 - Funding Information:
The following grant funding partially supported this study: LBRN Pilot and full project Awards (to JC) from an IDeA NIH/NIGMS grant P20GM12345 (to KK), an LBRN-INBRE-COBRE Administrative Supplement Award (to JC) from an IDeA NIH/NIGMS grant 3P20GM103424-18S1 (to KK); Louisiana Board of Regents Support Fund grants LEQSF (2021–24)-RD-A-22 (to JC). SE is supported by Program Project grant P01 HL088594 and Clinical and Translational Research Center grant UL1 RR025011 from the (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Acknowledgments
Publisher Copyright:
Copyright © 2023 Roy, Banang-Mbeumi, Boateng, Ruiz, Chamcheu, Kang, King, Walker, Nagalo, Kousoulas, Esnault, Huang and Chamcheu.
PY - 2023/1/18
Y1 - 2023/1/18
N2 - Psoriasis is a chronic autoimmune inflammatory skin disorder characterized by epidermal hyperplasia and aberrant immune response. In addition to aberrant cytokine production, psoriasis is associated with activation of the Akt/mTOR pathway. mTOR/S6K1 regulates T-lymphocyte activation and migration, keratinocytes proliferation and is upregulated in psoriatic lesions. Several drugs that target Th1/Th17 cytokines or their receptors have been approved for treating psoriasis in humans with variable results necessitating improved therapies. Fisetin, a natural dietary polyphenol with anti-oxidant and anti-proliferative properties, covalently binds mTOR/S6K1. The effects of fisetin on psoriasis and its underlying mechanisms have not been clearly defined. Here, we evaluated the immunomodulatory effects of fisetin on Th1/Th17-cytokine-activated adult human epidermal keratinocytes (HEKa) and anti-CD3/CD28-stimulated inflammatory CD4+ T cells and compared these activities with those of rapamycin (an mTOR inhibitor). Transcriptomic analysis of HEKa revealed 12,713 differentially expressed genes (DEGs) in the fisetin-treated group compared to 7,374 DEGs in the rapamycin-treated group, both individually compared to a cytokine treated group. Gene ontology analysis revealed enriched functional groups related to PI3K/Akt/mTOR signaling pathways, psoriasis, and epidermal development. Using in silico molecular modeling, we observed a high binding affinity of fisetin to IL-17A. In vitro, fisetin significantly inhibited mTOR activity, increased the expression of autophagy markers LC3A/B and Atg5 in HEKa cells and suppressed the secretion of IL-17A by activated CD4+ T lymphocytes or T lymphocytes co-cultured with HEKa. Topical administration of fisetin in an imiquimod (IMQ)-induced mouse psoriasis model exhibited a better effect than rapamycin in reducing psoriasis-like inflammation and Akt/mTOR phosphorylation and promoting keratinocyte differentiation and autophagy in mice skin lesions. Fisetin also significantly inhibited T-lymphocytes and F4/80+ macrophage infiltration into skin. We conclude that fisetin potently inhibits IL-17A and the Akt/mTOR pathway and promotes keratinocyte differentiation and autophagy to alleviate IMQ-induced psoriasis-like disease in mice. Altogether, our findings suggest fisetin as a potential treatment for psoriasis and possibly other inflammatory skin diseases.
AB - Psoriasis is a chronic autoimmune inflammatory skin disorder characterized by epidermal hyperplasia and aberrant immune response. In addition to aberrant cytokine production, psoriasis is associated with activation of the Akt/mTOR pathway. mTOR/S6K1 regulates T-lymphocyte activation and migration, keratinocytes proliferation and is upregulated in psoriatic lesions. Several drugs that target Th1/Th17 cytokines or their receptors have been approved for treating psoriasis in humans with variable results necessitating improved therapies. Fisetin, a natural dietary polyphenol with anti-oxidant and anti-proliferative properties, covalently binds mTOR/S6K1. The effects of fisetin on psoriasis and its underlying mechanisms have not been clearly defined. Here, we evaluated the immunomodulatory effects of fisetin on Th1/Th17-cytokine-activated adult human epidermal keratinocytes (HEKa) and anti-CD3/CD28-stimulated inflammatory CD4+ T cells and compared these activities with those of rapamycin (an mTOR inhibitor). Transcriptomic analysis of HEKa revealed 12,713 differentially expressed genes (DEGs) in the fisetin-treated group compared to 7,374 DEGs in the rapamycin-treated group, both individually compared to a cytokine treated group. Gene ontology analysis revealed enriched functional groups related to PI3K/Akt/mTOR signaling pathways, psoriasis, and epidermal development. Using in silico molecular modeling, we observed a high binding affinity of fisetin to IL-17A. In vitro, fisetin significantly inhibited mTOR activity, increased the expression of autophagy markers LC3A/B and Atg5 in HEKa cells and suppressed the secretion of IL-17A by activated CD4+ T lymphocytes or T lymphocytes co-cultured with HEKa. Topical administration of fisetin in an imiquimod (IMQ)-induced mouse psoriasis model exhibited a better effect than rapamycin in reducing psoriasis-like inflammation and Akt/mTOR phosphorylation and promoting keratinocyte differentiation and autophagy in mice skin lesions. Fisetin also significantly inhibited T-lymphocytes and F4/80+ macrophage infiltration into skin. We conclude that fisetin potently inhibits IL-17A and the Akt/mTOR pathway and promotes keratinocyte differentiation and autophagy to alleviate IMQ-induced psoriasis-like disease in mice. Altogether, our findings suggest fisetin as a potential treatment for psoriasis and possibly other inflammatory skin diseases.
KW - Akt/mTOR and IL-17A
KW - autophagy
KW - fisetin
KW - keratinocytes RNA-sequencing
KW - psoriasis
KW - psoriasis-like skin inflammation
KW - rapamycin
KW - topical administration
UR - http://www.scopus.com/inward/record.url?scp=85147224329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147224329&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.1075804
DO - 10.3389/fimmu.2022.1075804
M3 - Article
C2 - 36741386
AN - SCOPUS:85147224329
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1075804
ER -